TISIDB

Summary
Symbol	EIF3L
Name	eukaryotic translation initiation factor 3, subunit L
Aliases	HSPC021; HSPC025; EIF3S11; EIF3S6IP; EIF3EIP; eukaryotic translation initiation factor 3, subunit 6 interact ......
Chromosomal Location	22q
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm
Domain	PF10255 RNA polymerase I-associated factor PAF67
Function	Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in the initiation of protein synthesis (PubMed:17581632, PubMed:25849773, PubMed:27462815). The eIF-3 complex associates with the 40S ribosome and facilitates the recruitment of eIF-1, eIF-1A, eIF-2:GTP:methionyl-tRNAi and eIF-5 to form the 43S pre-initiation complex (43S PIC). The eIF-3 complex stimulates mRNA recruitment to the 43S PIC and scanning of the mRNA for AUG recognition. The eIF-3 complex is also required for disassembly and recycling of post-termination ribosomal complexes and subsequently prevents premature joining of the 40S and 60S ribosomal subunits prior to initiation (PubMed:17581632). The eIF-3 complex specifically targets and initiates translation of a subset of mRNAs involved in cell proliferation, including cell cycling, differentiation and apoptosis, and uses different modes of RNA stem-loop binding to exert either translational activation or repression (PubMed:25849773). ; FUNCTION: (Microbial infection) In case of FCV infection, plays a role in the ribosomal termination-reinitiation event leading to the translation of VP2 (PubMed:18056426).

> Gene Ontology [ TOP ]
Biological Process	GO:0001731 formation of translation preinitiation complex GO:0006413 translational initiation GO:0006417 regulation of translation GO:0006446 regulation of translational initiation GO:0010608 posttranscriptional regulation of gene expression GO:0019058 viral life cycle GO:0019080 viral gene expression GO:0019081 viral translation GO:0022613 ribonucleoprotein complex biogenesis GO:0022618 ribonucleoprotein complex assembly GO:0034248 regulation of cellular amide metabolic process GO:0044033 multi-organism metabolic process GO:0071826 ribonucleoprotein complex subunit organization GO:0075525 viral translational termination-reinitiation
Molecular Function	GO:0003743 translation initiation factor activity GO:0008135 translation factor activity, RNA binding
Cellular Component	GO:0001650 fibrillar center GO:0005852 eukaryotic translation initiation factor 3 complex GO:0016282 eukaryotic 43S preinitiation complex GO:0033290 eukaryotic 48S preinitiation complex GO:0044452 nucleolar part GO:0070993 translation preinitiation complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-157279: 3' -UTR-mediated translational regulation R-HSA-72662: Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S R-HSA-72737: Cap-dependent Translation Initiation R-HSA-72613: Eukaryotic Translation Initiation R-HSA-72689: Formation of a pool of free 40S subunits R-HSA-72695: Formation of the ternary complex, and subsequently, the 43S complex R-HSA-72706: GTP hydrolysis and joining of the 60S ribosomal subunit R-HSA-74160: Gene Expression R-HSA-156827: L13a-mediated translational silencing of Ceruloplasmin expression R-HSA-392499: Metabolism of proteins R-HSA-72702: Ribosomal scanning and start codon recognition R-HSA-72766: Translation R-HSA-72649: Translation initiation complex formation

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-157279: 3' -UTR-mediated translational regulation
R-HSA-72662: Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
R-HSA-72737: Cap-dependent Translation Initiation
R-HSA-72613: Eukaryotic Translation Initiation
R-HSA-72689: Formation of a pool of free 40S subunits
R-HSA-72695: Formation of the ternary complex, and subsequently, the 43S complex
R-HSA-72706: GTP hydrolysis and joining of the 60S ribosomal subunit
R-HSA-74160: Gene Expression
R-HSA-156827: L13a-mediated translational silencing of Ceruloplasmin expression
R-HSA-392499: Metabolism of proteins
R-HSA-72702: Ribosomal scanning and start codon recognition
R-HSA-72766: Translation
R-HSA-72649: Translation initiation complex formation

Summary
Symbol	EIF3L
Name	eukaryotic translation initiation factor 3, subunit L
Aliases	HSPC021; HSPC025; EIF3S11; EIF3S6IP; EIF3EIP; eukaryotic translation initiation factor 3, subunit 6 interact ......
Chromosomal Location	22q
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between EIF3L and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	EIF3L
Name	eukaryotic translation initiation factor 3, subunit L
Aliases	HSPC021; HSPC025; EIF3S11; EIF3S6IP; EIF3EIP; eukaryotic translation initiation factor 3, subunit 6 interact ......
Chromosomal Location	22q
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of EIF3L in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.6	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	EIF3L
Name	eukaryotic translation initiation factor 3, subunit L
Aliases	HSPC021; HSPC025; EIF3S11; EIF3S6IP; EIF3EIP; eukaryotic translation initiation factor 3, subunit 6 interact ......
Chromosomal Location	22q
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of EIF3L in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.134	0.509
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.004	0.999
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.224	0.93
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.363	0.59
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.398	0.863
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1.332	0.665
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.045	0.93
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.129	0.958
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.244	0.929
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.24	0.926
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.191	0.961
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.131	0.0488

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of EIF3L in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	2.7	4.7	0.294
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	1.7	5.7	0.231
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	EIF3L
Name	eukaryotic translation initiation factor 3, subunit L
Aliases	HSPC021; HSPC025; EIF3S11; EIF3S6IP; EIF3EIP; eukaryotic translation initiation factor 3, subunit 6 interact ......
Chromosomal Location	22q
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EIF3L. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	EIF3L
Name	eukaryotic translation initiation factor 3, subunit L
Aliases	HSPC021; HSPC025; EIF3S11; EIF3S6IP; EIF3EIP; eukaryotic translation initiation factor 3, subunit 6 interact ......
Chromosomal Location	22q
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EIF3L. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EIF3L. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	EIF3L
Name	eukaryotic translation initiation factor 3, subunit L
Aliases	HSPC021; HSPC025; EIF3S11; EIF3S6IP; EIF3EIP; eukaryotic translation initiation factor 3, subunit 6 interact ......
Chromosomal Location	22q
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EIF3L. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	EIF3L
Name	eukaryotic translation initiation factor 3, subunit L
Aliases	HSPC021; HSPC025; EIF3S11; EIF3S6IP; EIF3EIP; eukaryotic translation initiation factor 3, subunit 6 interact ......
Chromosomal Location	22q
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of EIF3L expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	EIF3L
Name	eukaryotic translation initiation factor 3, subunit L
Aliases	HSPC021; HSPC025; EIF3S11; EIF3S6IP; EIF3EIP; eukaryotic translation initiation factor 3, subunit 6 interact ......
Chromosomal Location	22q
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between EIF3L and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	EIF3L
Name	eukaryotic translation initiation factor 3, subunit L
Aliases	HSPC021; HSPC025; EIF3S11; EIF3S6IP; EIF3EIP; eukaryotic translation initiation factor 3, subunit 6 interact ......
Chromosomal Location	22q
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting EIF3L collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse EIF3L